ArticleJournal of cardiothoracic surgery2025
The diagnostic value of serum Cystatin C in differentiating malignant from benign pulmonary nodules: a retrospective cohort study.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe present study aims to evaluate the utility of Cystatin C testing for differentiating lung cancer from benign nodules of the lung in patient.
methodsConsecutive patients were enrolled in our research who had undergone a surgical resection or with fine needle biopsy between April 2015 and June 2024. All the patients were evaluated with their age, sex, smoking, drinking, and histology of lung cancer. Serum levels of Cystatin C in patients with lung nodules were evaluated using an automated analyzer.
results540 consecutive patients were enrolled in our research. There were 443 patients with primary lung cancer and 97 patients diagnosed as benign nodules. The serum level of Cys-C in patient with malignant nodule was significantly higher than in those with benign nodule (p<0.01), but they were comparable between patients with squamous cell carcinoma, adenocarcinoma, small cell lung cancer and large cell neuroendocrine carcinoma. Moreover, receiver operating characteristic curve analysis showed that a Cys-C level>0.92 mg/L was a good predictor for ruling out benign nodule, with a sensitivity of 64.0% and a specificity of 63%.
conclusionsOur study suggests that the serum Cys-C level test may be helpful for differentiating lung cancer from the benign nodule of the lung in patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.